

BEST AVAILABLE COPY

12/29/2005 09:17 FAX 7606033820

ISIS PATENT DEPT

→ PATENT OFFICE

003/005

Attorney Docket No.:
Serial No.:
Page 2

ISIS-5315 (ISIS No ISIS-2960US.P2)
10/698,689

This listing of claims will replace all prior versions and listings of claims in the application:

1-16. (Canceled)

17. (Original) A method of inhibiting the expression of CD40 in a cell or tissue comprising contacting said cell or tissue with the antisense compound of claim 1 so that expression of CD40 is inhibited.

18. (Original) The method of claim 17 wherein said cells are B-cells or macrophages.

19-22. (Canceled)

23. (Original) A method of treating an animal having a disease or condition associated with CD40 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of CD40 is inhibited.

24. (Original) The method of claim 23 wherein the disease or condition is an immune-associated disorder, an inflammatory condition or a hyperproliferative condition.

25. (Original) The method of claim 24 wherein the immune-associated disorder is graft-versus-host disease, allograft rejection or an autoimmune disease or condition.

26. (Original) The method of claim 24 wherein the inflammatory condition is asthma, rheumatoid arthritis, allograft rejection, inflammatory bowel disease or psoriasis.

BEST AVAILABLE COPY

12/29/2005 09:17 FAX 7606033820

ISIS PATENT DEPT

→ PATENT OFFICE

004/005

Attorney Docket No.:

ISIS-5315 (ISIS No ISIS-2960US.P2)

Serial No.:

10/698,689

Page 3

27. (Original) The method of claim 24 wherein the hyperproliferative condition is atherosclerosis, cancer or a tumor.

28-61. (Canceled)

62. (Original) A method of redirecting splicing of CD40 RNA in a cell or tissue comprising contacting said cell or tissue with an antisense compound of claim 57, so that the ratio of CD40 splice products is altered.

63. (Original) The method of claim 62 wherein the ratio of CD40 Type 2 transcript is increased relative to the CD40 Type 1 transcript.

64. (Original) The method of claim 63 wherein CD40 signaling is reduced.

65. (Original) The method of claim 64 wherein IL-12 cytokine production is reduced.

66. (Original) A method of reducing CD40 signaling in a cell or tissue comprising contacting said cell or tissue with an antisense compound of claim 57, so that the ratio of CD40 splice products is altered and CD40 signaling is reduced.

67. (Original) A method of reducing IL-12 cytokine production in a cell or tissue comprising contacting said cell or tissue with an antisense compound of claim 57, so that the ratio of CD40 splice products is altered and IL-12 cytokine production is reduced.

68-69. (Canceled)